{"created":"2023-05-15T15:02:49.354223+00:00","id":85155,"links":{},"metadata":{"_buckets":{"deposit":"8f8939fc-9a92-48c5-9e57-3ba829e0d9e9"},"_deposit":{"created_by":1,"id":"85155","owners":[1],"pid":{"revision_id":0,"type":"depid","value":"85155"},"status":"published"},"_oai":{"id":"oai:repo.qst.go.jp:00085155","sets":["1"]},"author_link":["1026505","1026510","1026509","1026513","1026506","1026515","1026507","1026508","1026511","1026514","1026516","1026512"],"item_8_biblio_info_7":{"attribute_name":"書誌情報","attribute_value_mlt":[{"bibliographicIssueDates":{"bibliographicIssueDate":"2021-12","bibliographicIssueDateType":"Issued"},"bibliographicIssueNumber":"2","bibliographicPageEnd":"732","bibliographicPageStart":"721","bibliographicVolumeNumber":"113","bibliographic_titles":[{"bibliographic_title":"Cancer  Science"}]}]},"item_8_description_5":{"attribute_name":"抄録","attribute_value_mlt":[{"subitem_description":"Synovial sarcomas are rare tumors arising in adolescents and young adults. The prognosis for advanced disease is poor, with an overall survival of 12-18 months. Frizzled homolog 10 (FZD10) is overexpressed in most synovial sarcomas, making it a promising therapeutic target. The results of a phase 1 trial of β-radioimmunotherapy (RIT) with the 90Y-labeled anti-FZD10 antibody OTSA101 revealed a need for improved efficacy. The present study evaluated the potential of α-RIT with OTSA101 labeled with the α-emitter 225Ac. Competitive inhibition and cell binding assays showed that specific binding of 225Ac-labeled OTSA101 to SYO-1 synovial sarcoma cells was comparable to that of the imaging agent 111In-labeled OTSA101. Biodistribution studies showed high uptake in SYO-1 tumors and low uptake in normal organs, except for blood. Dosimetric studies showed that the biologically effective dose (BED) of 225Ac-labeled OTSA101 for tumors was 7.8 Bd higher than that of 90Y-labeled OTSA101. 90Y- and 225Ac-labeled OTSA101 decreased tumor volume and prolonged survival. 225Ac-labeled OTSA101 achieved a complete response in 60% of mice, and no recurrence was observed. 225Ac-labeled OTSA101 induced a larger amount of necrosis and apoptosis than 90Y-labeled OTSA101, although the cell proliferation decrease was comparable. The BED for normal organs and tissues was tolerable; no treatment-related mortality or obvious toxicity, except for temporary body weight loss, was observed. 225Ac-labeled OTSA101 provided a high BED for tumors and achieved a 60% complete response in the synovial sarcoma mouse model SYO-1. RIT with 225Ac-labeled OTSA101 is a promising therapeutic option for synovial sarcoma.","subitem_description_type":"Abstract"}]},"item_8_publisher_8":{"attribute_name":"出版者","attribute_value_mlt":[{"subitem_publisher":"Wiley Online Library"}]},"item_8_relation_13":{"attribute_name":"PubMed番号","attribute_value_mlt":[{"subitem_relation_type_id":{"subitem_relation_type_id_text":"34935247","subitem_relation_type_select":"PMID"}}]},"item_8_relation_14":{"attribute_name":"DOI","attribute_value_mlt":[{"subitem_relation_type_id":{"subitem_relation_type_id_text":"10.1111/cas.15235","subitem_relation_type_select":"DOI"}}]},"item_8_relation_17":{"attribute_name":"関連サイト","attribute_value_mlt":[{"subitem_relation_type_id":{"subitem_relation_type_id_text":"https://onlinelibrary.wiley.com/doi/full/10.1111/cas.15235","subitem_relation_type_select":"URI"}}]},"item_8_source_id_9":{"attribute_name":"ISSN","attribute_value_mlt":[{"subitem_source_identifier":"1347-9032","subitem_source_identifier_type":"ISSN"}]},"item_access_right":{"attribute_name":"アクセス権","attribute_value_mlt":[{"subitem_access_right":"metadata only access","subitem_access_right_uri":"http://purl.org/coar/access_right/c_14cb"}]},"item_creator":{"attribute_name":"著者","attribute_type":"creator","attribute_value_mlt":[{"creatorNames":[{"creatorName":"Hitomi, Sudo"}],"nameIdentifiers":[{"nameIdentifier":"1026505","nameIdentifierScheme":"WEKO"}]},{"creatorNames":[{"creatorName":"Atsushi, Tsuji"}],"nameIdentifiers":[{"nameIdentifier":"1026506","nameIdentifierScheme":"WEKO"}]},{"creatorNames":[{"creatorName":"Aya, Sugyo"}],"nameIdentifiers":[{"nameIdentifier":"1026507","nameIdentifierScheme":"WEKO"}]},{"creatorNames":[{"creatorName":"Yosuke , Harada"}],"nameIdentifiers":[{"nameIdentifier":"1026508","nameIdentifierScheme":"WEKO"}]},{"creatorNames":[{"creatorName":"Satoshi , Nagayama"}],"nameIdentifiers":[{"nameIdentifier":"1026509","nameIdentifierScheme":"WEKO"}]},{"creatorNames":[{"creatorName":"Toyomasa , Katagiri"}],"nameIdentifiers":[{"nameIdentifier":"1026510","nameIdentifierScheme":"WEKO"}]},{"creatorNames":[{"creatorName":"Yusuke , Nakamura"}],"nameIdentifiers":[{"nameIdentifier":"1026511","nameIdentifierScheme":"WEKO"}]},{"creatorNames":[{"creatorName":"Tatsuya, Higashi"}],"nameIdentifiers":[{"nameIdentifier":"1026512","nameIdentifierScheme":"WEKO"}]},{"creatorNames":[{"creatorName":"Hitomi, Sudo","creatorNameLang":"en"}],"nameIdentifiers":[{"nameIdentifier":"1026513","nameIdentifierScheme":"WEKO"}]},{"creatorNames":[{"creatorName":"Atsushi, Tsuji","creatorNameLang":"en"}],"nameIdentifiers":[{"nameIdentifier":"1026514","nameIdentifierScheme":"WEKO"}]},{"creatorNames":[{"creatorName":"Aya, Sugyo","creatorNameLang":"en"}],"nameIdentifiers":[{"nameIdentifier":"1026515","nameIdentifierScheme":"WEKO"}]},{"creatorNames":[{"creatorName":"Tatsuya, Higashi","creatorNameLang":"en"}],"nameIdentifiers":[{"nameIdentifier":"1026516","nameIdentifierScheme":"WEKO"}]}]},"item_language":{"attribute_name":"言語","attribute_value_mlt":[{"subitem_language":"eng"}]},"item_resource_type":{"attribute_name":"資源タイプ","attribute_value_mlt":[{"resourcetype":"journal article","resourceuri":"http://purl.org/coar/resource_type/c_6501"}]},"item_title":"FZD10-targeted α-radioimmunotherapy with 225Ac-labeled OTSA101 achieves complete remission in a synovial sarcoma model","item_titles":{"attribute_name":"タイトル","attribute_value_mlt":[{"subitem_title":"FZD10-targeted α-radioimmunotherapy with 225Ac-labeled OTSA101 achieves complete remission in a synovial sarcoma model"}]},"item_type_id":"8","owner":"1","path":["1"],"pubdate":{"attribute_name":"公開日","attribute_value":"2021-12-22"},"publish_date":"2021-12-22","publish_status":"0","recid":"85155","relation_version_is_last":true,"title":["FZD10-targeted α-radioimmunotherapy with 225Ac-labeled OTSA101 achieves complete remission in a synovial sarcoma model"],"weko_creator_id":"1","weko_shared_id":-1},"updated":"2023-05-15T17:58:20.747989+00:00"}